Free Trial

Ligand Pharmaceuticals (LGND) Short Interest Ratio & Short Volume

Ligand Pharmaceuticals logo
$111.56 -0.24 (-0.21%)
(As of 11/20/2024 ET)

Ligand Pharmaceuticals Short Interest Data

Ligand Pharmaceuticals (LGND) has a short interest of 918,600 shares. This marks a -8.14% decrease in short interest from the previous month. The short interest ratio (days to cover) is 8.5, indicating that it would take 8.5 days of the average trading volume of 144,630 shares to cover all short positions.

Current Short Interest
918,600 shares
Previous Short Interest
1,000,000 shares
Change Vs. Previous Month
-8.14%
Dollar Volume Sold Short
$97.10 million
Short Interest Ratio
8.5 Days to Cover
Last Record Date
October 31, 2024
Outstanding Shares
18,900,000 shares
Percentage of Shares Shorted
4.86%
Today's Trading Volume
133,450 shares
Average Trading Volume
144,630 shares
Today's Volume Vs. Average
92%
Short Selling Ligand Pharmaceuticals?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Ligand Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

LGND Short Interest Over Time

LGND Days to Cover Over Time

LGND Percentage of Float Shorted Over Time

Ligand Pharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/31/2024918,600 shares $97.10 million -8.1%N/A8.5 $105.70
10/15/20241,000,000 shares $104.39 million +0.4%N/A9.5 $104.39
9/30/2024996,100 shares $99.70 million +1.9%N/A8.7 $100.09
9/15/2024977,400 shares $102.40 million -1.8%N/A7.9 $104.77
8/31/2024995,000 shares $105.27 million -6.1%N/A8.1 $105.80
8/15/20241,060,000 shares $109.32 million +10.3%N/A8.3 $103.13
7/31/2024960,700 shares $104.71 million -12.7%N/A6.9 $108.99
7/15/20241,100,000 shares $106.34 million +17.7%N/A7.9 $96.67
6/30/2024934,400 shares $78.73 million -0.2%N/A6.5 $84.26
6/15/2024936,600 shares $74.98 million +32.3%N/A6.6 $80.06
5/31/2024707,700 shares $60.19 million -17.6%N/A4.3 $85.05
5/15/2024858,700 shares $73.65 million +7.9%N/A4.6 $85.77
4/30/2024795,600 shares $55.60 million -3.8%N/A4.3 $69.89
4/15/2024826,600 shares $65.94 million +23.0%5.0%4.9 $79.77
3/31/2024672,100 shares $49.13 million -23.3%4.1%4.1 $73.10
3/15/2024876,300 shares $62.30 million +14.9%5.3%5.8 $71.09
2/29/2024762,600 shares $60.51 million -15.0%4.6%5.3 $79.35
2/15/2024896,600 shares $66.93 million -3.6%5.5%7.3 $74.65
1/31/2024929,800 shares $67.97 million +1.0%5.7%8.1 $73.10
1/15/2024920,700 shares $66.84 million +2.2%6.9%8.2 $72.60
12/31/2023900,800 shares $64.34 million +0.8%5.5%8.2 $71.42
12/15/2023893,600 shares $60.18 million -1.7%5.5%8.1 $67.35
11/30/2023909,100 shares $53.01 million -2.3%5.5%8.8 $58.31
11/15/2023930,200 shares $52.54 million +6.1%5.7%9.2 $56.48
10/31/2023876,400 shares $45.83 million +3.8%5.4%8.8 $52.29
10/15/2023844,700 shares $46.45 million +2.5%5.2%8.8 $54.99
9/30/2023824,100 shares $49.38 million -0.1%5.1%8.4 $59.92
9/15/2023825,000 shares $51.13 million -6.2%5.1%8.8 $61.98
8/31/2023879,200 shares $57.82 million +4.6%5.4%9.1 $65.77
8/15/2023840,500 shares $56.81 million +4.3%5.2%8.6 $67.59
7/31/2023805,800 shares $53.93 million -3.4%5.0%8.2 $66.93
7/15/2023834,300 shares $56.61 million -1.4%5.1%8.4 $67.85
6/30/2023846,200 shares $61.01 million +4.0%5.2%8.6 $72.10
6/15/2023814,000 shares $64.30 million -1.6%5.0%7.8 $78.99
5/31/2023827,100 shares $57.96 million +1.3%5.1%7.9 $70.08
5/15/2023816,400 shares $63.34 million +0.7%5.0%7.2 $77.59
4/30/2023811,100 shares $61.93 million +5.1%5.1%7 $76.35
4/15/2023771,800 shares $57.38 million -1.0%4.8%6.6 $74.34
3/31/2023779,200 shares $57.32 million -13.5%4.9%6.5 $73.56
3/15/2023900,500 shares $64.48 million +7.5%5.6%7.1 $71.61
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

2/28/2023838,100 shares $60.46 million +2.5%5.2%5.1 $72.14
2/15/2023817,900 shares $59.69 million +1.5%5.1%4.8 $72.98
1/31/2023806,000 shares $56.18 million +0.1%5.1%4.6 $69.70
1/15/2023805,000 shares $57.38 million +1.5%5.1%4.1 $71.28
12/30/2022792,800 shares $52.96 million -8.4%5.0%4.1 $66.80
12/15/2022865,800 shares $53.81 million +13.0%5.5%4.4 $62.15
11/30/2022766,100 shares $55.85 million -2.3%4.8%4.6 $72.90
11/15/2022784,100 shares $61.99 million +6.6%4.9%5 $79.06
10/31/2022735,400 shares $64.46 million -0.3%4.6%5 $87.65
10/15/2022737,800 shares $66.03 million -6.7%4.6%6 $89.49
9/30/2022790,600 shares $68.08 million -5.1%5.0%6.6 $86.11
9/15/2022833,000 shares $75.08 million +3.1%5.2%7 $90.13
8/31/2022808,200 shares $74.67 million -3.7%5.1%6.6 $92.39
8/15/2022839,000 shares $90.03 million -3.2%5.3%6.8 $107.31
7/31/2022866,700 shares $79.76 million -0.8%5.4%6.5 $92.03
7/15/2022873,600 shares $82.58 million -3.6%5.4%6 $94.53
6/30/2022905,800 shares $80.82 million -0.2%5.6%6 $89.22
6/15/2022907,900 shares $71.80 million -0.6%N/A5.7 $79.08
5/31/2022913,400 shares $81.21 million -10.5%5.7%6.2 $88.91
5/15/20221,020,000 shares $87.68 million -8.9%6.4%6.2 $85.96
4/30/20221,120,000 shares $104.00 million No Change7.0%6.8 $92.86
4/15/20221,120,000 shares $117.89 million -8.9%7.0%6.8 $105.26
3/31/20221,230,000 shares $138.36 million +2.5%7.7%7.2 $112.49
3/15/20221,200,000 shares $125.44 million -2.4%7.5%7.5 $104.53
2/28/20221,230,000 shares $124.50 million No Change7.7%7.7 $101.22
2/15/20221,230,000 shares $152.13 million -10.2%7.8%8.1 $123.68
1/31/20221,370,000 shares $170.74 million -11.0%8.6%9.7 $124.63
1/15/20221,540,000 shares $192.36 million -4.4%9.7%11.3 $124.91
12/31/20211,610,000 shares $248.68 million -4.2%10.1%13.4 $154.46
12/15/20211,680,000 shares $247.80 million +5.0%10.6%13.9 $147.50
11/30/20211,600,000 shares $259.07 million +0.6%10.1%13.5 $161.92
11/15/20211,590,000 shares $260.93 million -4.2%10.0%8 $164.11
10/29/20211,660,000 shares $242.26 million No Change10.5%8 $145.94
10/15/20211,660,000 shares $216.23 million -4.1%10.5%7.9 $130.26
9/30/20211,730,000 shares $241.02 million -2.8%10.9%8 $139.32
9/15/20211,780,000 shares $241.83 million +10.6%11.2%7.8 $135.86
8/31/20211,610,000 shares $213.00 million -0.6%10.2%7 $132.30
8/13/20211,620,000 shares $173.05 million -1.8%10.2%10.1 $106.82
7/30/20211,650,000 shares $187.29 million -6.3%10.4%11 $113.51
7/15/20211,760,000 shares $203.84 million +0.6%11.1%11.7 $115.82
6/30/20211,750,000 shares $229.58 million +1.7%11.0%11.7 $131.19
6/15/20211,720,000 shares $212.97 million +8.2%10.8%12 $123.82
5/28/20211,590,000 shares $187.14 million -0.6%10.0%9.8 $117.70
5/14/20211,600,000 shares $198.21 million -0.6%10.1%8.5 $123.88
4/30/20211,610,000 shares $234.69 million +2.6%10.1%6.1 $145.77
4/15/20211,570,000 shares $237.12 million +4.7%9.9%2.9 $151.03
3/31/20211,500,000 shares $223.67 million -19.4%9.5%2.6 $149.11
3/15/20211,860,000 shares $306.49 million -15.8%11.8%3 $164.78
2/26/20212,210,000 shares $331.96 million -19.3%14.0%3.6 $150.21
2/12/20212,740,000 shares $493.31 million -54.1%17.9%4.5 $180.04
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

1/29/20215,970,000 shares $1.14 billion -40.4%38.9%10.3 $191.59
1/15/202110,010,000 shares $1.22 billion +1.0%64.9%21.5 $122.28
12/31/20209,910,000 shares $1.02 billion -0.7%64.2%28.9 $102.63
12/15/20209,980,000 shares $1.02 billion -1.6%64.7%29.5 $101.79
11/30/202010,140,000 shares $871.23 million -4.6%65.7%30.6 $85.92
11/15/202010,630,000 shares $889.84 million -1.0%68.9%32.7 $83.71
10/30/202010,740,000 shares $892.17 million +5.1%69.6%34.8 $83.07
10/15/202010,220,000 shares $1.02 billion +3.9%66.2%34.7 $100.01
9/30/20209,840,000 shares $937.95 million +6.0%63.8%39.7 $95.32
9/15/20209,280,000 shares $890.79 million +3.0%60.1%35 $95.99
8/31/20209,010,000 shares $919.02 million +0.9%58.4%34.6 $102.00
8/14/20208,930,000 shares $1.01 billion +4.6%57.9%31.6 $113.25
7/31/20208,540,000 shares $1.00 billion -3.3%55.5%27.5 $117.18
7/15/20208,830,000 shares $1.05 billion -1.9%57.3%26.7 $119.42
6/30/20209,000,000 shares $1.01 billion -4.8%58.3%24.6 $111.85
6/15/20209,450,000 shares $1.05 billion +2.1%61.2%22.3 $111.49
5/29/20209,260,000 shares $940.54 million -1.9%59.7%17.9 $101.57
5/15/20209,440,000 shares $932.20 million +2.8%60.9%16.8 $98.75
4/30/20209,180,000 shares $904.87 million -2.9%59.2%16.3 $98.57
4/15/20209,450,000 shares $835.19 million +2.2%59.7%17.1 $88.38
3/31/20209,250,000 shares $903.08 million +3.9%58.4%17.1 $97.63
3/13/20208,904,900 shares $769.56 million +12.6%56.1%14.1 $86.42
2/28/20207,910,000 shares $557.97 million +3.1%49.8%20.8 $70.54
2/14/20207,670,000 shares $752.58 million -0.1%45.4%24.4 $98.12
1/31/20207,680,000 shares $788.12 million -0.9%45.3%24.3 $102.62
1/15/20207,750,000 shares $734.39 million -0.3%45.7%23.8 $94.76
12/31/20197,770,000 shares $687.96 million +1.0%45.8%25 $88.54

LGND Short Interest - Frequently Asked Questions

What is Ligand Pharmaceuticals' current short interest?

Short interest is the volume of Ligand Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of October 31st, traders have sold 918,600 shares of LGND short. Learn More on Ligand Pharmaceuticals' current short interest.

What is a good short interest ratio for Ligand Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LGND shares currently have a short interest ratio of 8.0. Learn More on Ligand Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Ligand Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Ligand Pharmaceuticals: Walleye Capital LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Ligand Pharmaceuticals' short interest increasing or decreasing?

Ligand Pharmaceuticals saw a decrease in short interest during the month of October. As of October 31st, there was short interest totaling 918,600 shares, a decrease of 8.1% from the previous total of 1,000,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Ligand Pharmaceuticals' short interest compare to its competitors?

Here is how the short interest of companies in the sector of "medical" compare to Ligand Pharmaceuticals: Nurix Therapeutics, Inc. (13.35%), Travere Therapeutics, Inc. (10.24%), Praxis Precision Medicines, Inc. (9.99%), Arcturus Therapeutics Holdings Inc. (18.50%), COMPASS Pathways plc (7.97%), Shattuck Labs, Inc. (5.31%), Repligen Co. (6.33%), Madrigal Pharmaceuticals, Inc. (20.77%), Halozyme Therapeutics, Inc. (8.14%), Ionis Pharmaceuticals, Inc. (7.37%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

What does it mean to sell short Ligand Pharmaceuticals stock?

Short selling LGND is an investing strategy that aims to generate trading profit from Ligand Pharmaceuticals as its price is falling. LGND shares are trading down $0.24 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Ligand Pharmaceuticals?

A short squeeze for Ligand Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LGND, which in turn drives the price of the stock up even further.

How often is Ligand Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LGND, twice per month. The most recent reporting period available is October, 31 2024.




This page (NASDAQ:LGND) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners